A venture fund has to return capital on a schedule. The FDA does not care about your schedule. That is the entire reason Hillman Ventures structures investments around regulatory milestones rather than fundraising rounds.
The structural mismatch
The standard venture fund has a ten-year life. Capital deployment in years one through four. Portfolio management in years three through eight. Distribution in years six through ten. The fund manager has to return capital to LPs on that schedule because the fund agreement requires it.
This works fine for software. Software deployment cycles are short. A SaaS product can be in market in twelve months. Venture mechanics align with product mechanics.
It does not work for FDA-regulated biotech. Mechanics differ.
A typical 351(a) BLA biologics program runs eight to fifteen years from founding to approved product. The venture clock and the science clock cannot both win. One forces the sale of the asset before peak value. The other delivers full value but past the fund window.
What family office capital does differently
A family office investing personal capital has no LP commitments and no fund agreement. The asset can hold across the full regulatory cycle without forced liquidity. If the IND filing takes three years instead of two, the family office waits. If Phase 2 takes four years instead of three, the family office waits. The patience is structural, not personal.
Three practical consequences.
Deal selection changes. Family office capital can pursue programs venture cannot. A program with a five-year IND timeline is uninvestable for a typical venture fund. Perfectly investable for a family office.
Valuation discipline changes. Without the pressure to deploy capital on a schedule, the family office can walk from overpriced rounds. Venture funds with deployment targets often pay above fair value because returning undeployed capital to LPs is the worse outcome.
Exit timing changes. The family office can hold a position through the long approval cycle and exit at peak value, often by partnering rather than selling.
The trade-offs
Family office capital is slower to deploy than venture. It often passes on programs venture will fund. It does not have the operational support infrastructure that larger venture firms provide. It does not write the largest checks.
For founders who need fast deployment, full-service support, and access to follow-on rounds at scale, venture is the right fit.
For founders building real regulated science with long regulatory horizons, family office capital is often the better fit, and sometimes the only fit. The patience requirement is structural. A founder who cannot get to IND in two years but can in three cannot work with a fund that needs IND in two. The fund's mechanics force a sale or write-down before the science is ready.
The match between capital structure and regulatory timeline is the central design question for any biotech founder thinking about who to take money from. Most founders default to venture because venture is what they know. Many end up in the bad place where the fund's clock runs out before the science is ready.
For founders building real regulated science, family office capital deserves a serious look.